GlassScriptPhysician profile
Ramona M Ball
NPI 1578010088
$9,164.74
in general payments reported to CMS, 2019-2025
55 companies · $2,245 in 2025
The $2,245 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,116 · 2022: $1,839 · 2023: $1,671 · 2024: $2,293 · 2025: $2,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,209.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $937.83 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $722.66 | 2021-2025 | Keytruda, Lynparza, Reblozyl |
| Janssen Biotech, INC. | $502.90 | 2022-2025 | Tecvayli, Darzalex, Rybrevant |
| Genentech USA, INC. | $499.99 | 2021-2025 | Polivy, Venclexta, Tecentriq |
| Incyte Corporation | $437.40 | 2021-2025 | Monjuvi, Jakafi |
| Tersera Therapeutics LLC | $402.11 | 2021-2025 | Zoladex, Xermelo, Quzyttir |
| Gilead Sciences, INC. | $393.23 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $348.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.09 | 2021-2025 | Ninlaro, Iclusig, Alunbrig |
| Celgene Corporation | $298.65 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $287.59 | 2021-2024 | Enhertu, Injectafer |
| Lilly USA, LLC | $277.35 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $270.87 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $253.70 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Beigene USA, INC. | $226.38 | 2021-2025 | Brukinsa, Tevimbra |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $210.28 | 2021-2025 | Vyloy, Padcev, Xtandi |
| Seagen INC. | $197.27 | 2021-2023 | Tukysa, Adcetris |
| Eisai INC. | $169.78 | 2021-2024 | |
| Sobi, INC | $161.09 | 2022-2025 | |
| Stemline Therapeutics INC. | $141.81 | 2023-2025 | Orserdu |
| Abbvie INC. | $141.16 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $130.62 | 2022-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $130.44 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $122.90 | 2023-2025 | Somatuline Depot, Onivyde, Tazverik |
| Puma Biotechnology, INC. | $122.70 | 2021-2025 | Nerlynx |
| E.R. Squibb & Sons, L.L.C. | $121.14 | 2022-2025 | Opdivo |
| Rigel Pharmaceuticals, INC. | $103.97 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pharmacosmos Therapeutics INC. | $99.77 | 2023-2024 | Monoferric, Cosela |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Array Biopharma INC | $87.00 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Emd Serono, INC. | $85.27 | 2022-2025 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $80.24 | 2021-2025 | |
| Exelixis INC. | $71.08 | 2021-2025 | Cabometyx |
| Amgen INC. | $71.00 | 2021 | |
| G1 Therapeutics, INC. | $66.31 | 2022-2023 | Cosela |
| Pharmacyclics LLC, An Abbvie Company | $55.35 | 2021-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $51.51 | 2021-2022 | |
| Blueprint Medicines Corporation | $50.83 | 2022 | |
| Pharmaessentia USA Corporation | $50.56 | 2023-2024 | Besremi |
| Mirati Therapeutics, INC. | $50.37 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.29 | 2021-2025 | |
| Kite Pharma, INC. | $33.48 | 2021-2025 | Yescarta |
| Acceleron Pharma, INC. | $32.33 | 2021 | |
| Sanofi US Services INC. | $22.96 | 2025 | |
| Taiho Oncology, INC. | $21.17 | 2025 | |
| Dova Pharmaceuticals | $19.66 | 2021 | |
| Sanofi Pasteur INC. | $18.95 | 2025 | |
| Aveo Pharmaceuticals, INC. | $17.35 | 2025 | |
| Karyopharm Therapeutics INC. | $16.93 | 2025 | Xpovio |
| Pharming Healthcare, INC. | $15.52 | 2025 | Ruconest |
| Novocure INC. | $14.92 | 2025 | Optune Lua (Novottf-200t) |
| Coherus Oncology, INC. | $14.18 | 2025 | Loqtorzi |
| Azurity Pharmaceuticals, INC. | $14.05 | 2024 | Vivimusta |
| Apellis Pharmaceuticals, INC. | $13.41 | 2024 | Empaveli |
| Morphosys, US INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramona Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.